Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-10T10:08:23.594Z Has data issue: false hasContentIssue false

Health technology assessment and policy from the economic perspective

Published online by Cambridge University Press:  23 April 2004

Frans Rutten
Affiliation:
Erasmus University Medical Centre, Rotterdam

Abstract

This article comments on the four country papers in this volume from an economic perspective. Different phases of the decision-making process, which can be supported by Health Technology Assessment (HTA), are considered. For each of these, there is large cross-country variation in the way in which HTA influences policy. Furthermore, economic themes regarding the relevance of HTA evidence for policy making, the position of cost-effectiveness in relation to other criteria vis-à-vis reimbursement decisions, the use of a cost per quality-adjusted life year threshold, and the incorporation of economic considerations in practice guidelines are discussed.

Type
Research Article
Copyright
© 2004 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Banta HD. 1997 Report from the EUR-ASSESS Project. Int J Technol Assess Health Care. 13; 133143.Google Scholar
Herings RMC, Leufkens HGM, Heerding ER, Klungel OH, Breekveldt-Postma NS. 2002 Chronic pharmacotherapy forever. Utrecht: Pharmo Institute;
Hill SR, Mitchell AS, Henry DA. 2000 Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 283; 21162121.Google Scholar
Rutten F, van Busschbach J. 2001 How to define a basic package of health services for a tax funded or social insurance based health care system? Eur J Health Economics. 2; 4546.Google Scholar